Enhanced anti-cancer activities of some derivatives of titanocene dichloride

The compounds ( η 5-C 5H 5) 2TiCl 2 ( I), currently undergoing phase II trials, ( η 5-C 5H 5)( η 5-C 5H 4CO 2Me)TiCl 2 ( II) and ( η 5-C 5H 4CO 2Me) 2TiCl 2 ( III) are assessed for their efficacies against a small lung cancer cell line. It is found that the introduction of the electron withdrawing c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of inorganic biochemistry 2001-03, Vol.84 (1), p.159-162
Main Authors: Boyles, John R., Baird, Michael C., Campling, Barbara G., Jain, Nidhi
Format: Article
Language:English
Subjects:
Anti-cancer drugs
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Carcinoma, Small Cell - drug therapy
Humans
Lung Neoplasms - drug therapy
Metallocenes
Organometallic Compounds - chemistry
Organometallic Compounds - pharmacology
Titanocene dichloride
Tumor Cells, Cultured
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The compounds ( η 5-C 5H 5) 2TiCl 2 ( I), currently undergoing phase II trials, ( η 5-C 5H 5)( η 5-C 5H 4CO 2Me)TiCl 2 ( II) and ( η 5-C 5H 4CO 2Me) 2TiCl 2 ( III) are assessed for their efficacies against a small lung cancer cell line. It is found that the introduction of the electron withdrawing carbomethoxy group into the cyclopentadienyl rings increases the effectiveness of this class of drugs, such that III compares favorably with the well known cisplatin.
ISSN:0162-0134
1873-3344
DOI:10.1016/S0162-0134(00)00203-8